FY2025 EPS Estimate for Brainsway Decreased by Analyst

Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY) – Equities research analysts at HC Wainwright reduced their FY2025 earnings per share (EPS) estimates for shares of Brainsway in a report issued on Thursday, November 13th. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn $0.38 per share for the year, down from their previous forecast of $0.40. HC Wainwright currently has a “Buy” rating and a $18.00 price target on the stock. The consensus estimate for Brainsway’s current full-year earnings is $0.08 per share. HC Wainwright also issued estimates for Brainsway’s Q4 2025 earnings at $0.14 EPS, Q2 2026 earnings at $0.14 EPS, Q3 2026 earnings at $0.22 EPS, Q4 2026 earnings at $0.28 EPS and FY2026 earnings at $0.76 EPS.

Brainsway (NASDAQ:BWAY) last issued its earnings results on Tuesday, November 11th. The company reported $0.08 EPS for the quarter, missing the consensus estimate of $0.11 by ($0.03). Brainsway had a return on equity of 9.46% and a net margin of 12.73%.The business had revenue of $13.51 million for the quarter, compared to analyst estimates of $13.04 million. Brainsway has set its FY 2025 guidance at EPS.

Other research analysts have also recently issued reports about the company. Weiss Ratings reiterated a “hold (c)” rating on shares of Brainsway in a research note on Tuesday, November 11th. Wall Street Zen cut Brainsway from a “buy” rating to a “hold” rating in a report on Saturday. Finally, Northland Securities increased their target price on Brainsway from $19.00 to $23.00 and gave the company an “outperform” rating in a research report on Wednesday, November 12th. Two analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, Brainsway presently has an average rating of “Moderate Buy” and an average target price of $20.50.

Brainsway Price Performance

Shares of NASDAQ:BWAY opened at $15.18 on Monday. Brainsway has a one year low of $7.84 and a one year high of $17.92. The company has a market cap of $296.92 million, a price-to-earnings ratio of 50.60 and a beta of 1.22. The firm has a 50 day simple moving average of $15.81 and a 200 day simple moving average of $13.37.

Hedge Funds Weigh In On Brainsway

A number of hedge funds have recently bought and sold shares of BWAY. ARK Investment Management LLC lifted its holdings in Brainsway by 7.3% in the first quarter. ARK Investment Management LLC now owns 188,328 shares of the company’s stock valued at $1,783,000 after buying an additional 12,740 shares during the period. Eagle Global Advisors LLC acquired a new position in shares of Brainsway in the 1st quarter valued at about $590,000. Trexquant Investment LP bought a new stake in shares of Brainsway during the 1st quarter valued at about $129,000. NewEdge Advisors LLC grew its stake in Brainsway by 61.5% during the first quarter. NewEdge Advisors LLC now owns 19,828 shares of the company’s stock worth $188,000 after purchasing an additional 7,549 shares during the period. Finally, Huntleigh Advisors Inc. increased its holdings in Brainsway by 5.7% in the second quarter. Huntleigh Advisors Inc. now owns 77,416 shares of the company’s stock worth $1,018,000 after purchasing an additional 4,143 shares in the last quarter. Institutional investors own 30.11% of the company’s stock.

About Brainsway

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.